References
- Knutson KL, Wagner W, Disis ML. Adoptive T cell therapy for solid cancers. Cancer Immunol Immunother 2005; 54: 721–8
- Dudley ME, Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666–75
- Cooley S, June CH, Schoenberger SP, Miller JS. Adoptive therapy with T cells/NK cells. Biol Blood Marrow Transplant 2007; 13: 33–42
- Dillman RO, Soori G, DePriest C, Nayak SK, Beutel LD, Schiltz PM, et al. Treatment of human solid malignancies with autologous activated lymphocytes and cimetidine: A phase II trial of the cancer biotherapy research group. Cancer Biother Radiopharm 2003; 18: 727–33
- Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 2004; 101: 14639–45
- Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850–4
- Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997; 80: 42–9
- Kobari M, Egawa S, Shibuya K, Sunamura M, Saitoh K, Matsuno S. Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. Br J Surg 2000; 87: 43–8
- Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000; 356: 802–7